SCHEMBL5338783

SCHEMBL5338783

Nc1ccc(/C(=C\c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.64
CYP19A1 P11511 4/20 0.57
CYP11B2 P19099 2/20 0.57
CYP1B1 Q16678 1/20 0.50
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
PTGS2 P35354 4/20 0.49
ESR2 Q92731 2/20 0.48
CYP2D6 P10635 1/20 0.47
NPC1 O15118 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PRMT1 Q99873 1/20 0.44
AKR1C1 Q04828 1/20 0.44
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2786938 1.00 ESR1 (0.64) ESR1CYP19A1CYP11B2CYP1B1MAOA
SCHEMBL28001312 0.94 ESR1 (0.58) ESR1CYP19A1CYP11B2CYP1B1MAOA
SCHEMBL28001314 0.94 ESR1 (0.58) ESR1CYP19A1CYP11B2CYP1B1MAOA
SCHEMBL2212092 0.94 CYP19A1 (0.59) ESR1CYP19A1CYP11B2CYP1B1MAOA
SCHEMBL4612465 0.89 ESR1 (0.78) ESR1CYP19A1CYP11B2PTGS2ESR2
SCHEMBL28143022 0.88 CYP19A1 (0.53) ESR1CYP19A1CYP11B2CYP1B1MAOA
SCHEMBL26867242 0.87 PTGS2 (0.63) ESR1CYP19A1CYP11B2PTGS2ESR2
SCHEMBL29195200 0.87 PTGS2 (0.63) ESR1CYP19A1CYP11B2PTGS2ESR2
SCHEMBL55433 0.87 ESR1 (0.74) ESR1CYP19A1CYP11B2PTGS2ESR2
Benzene SCHEMBL27868814 0.87 ESR1 (0.74) ESR1CYP19A1CYP11B2PTGS2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007098090-A2 TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH N-OXIDES OF ESTROGEN RECEPTOR MODULATORS NOVACEA, INC. (US) 2007-08-30 WO disclosed
EP-0720597-B1 TRIARYL-ETHYLENE DERIVATIVES FOR USE IN THERAPY MERRELL PHARMA INC (US) 1998-04-29 EP disclosed
US-5693674-A Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis HOECHST MARION ROUSSEL, INC. (US) 1997-12-02 US disclosed
US-5691384-A Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis HOECHST MARION ROUSSEL, INC. (US) 1997-11-25 US disclosed
US-5684004-A ANTINEOPLASTIC AGENTS, ANTIATHEROSCLEROTIC AGENTS, HYPOCHOLESTEROLEMIC AGENTS MERRELL PHARMACEUTICALS, INC. (US) 1997-11-04 US disclosed
EP-0794771-A1 METHOD OF USING TRIARYL-ETHYLENE DERIVATIVES IN THE TREATMENT AND PREVENTION OF OSTEOPOROSIS HOECHST MARION ROUSSEL, INC. (US) 1997-09-17 EP disclosed
EP-0720597-A1 TRIARYL-ETHYLENE DERIVATIVES FOR USE IN THERAPY MERRELL PHARMACEUTICALS INC. (US) 1996-07-10 EP disclosed
US-5525633-A ANTITUMOR AGENTS, ANTICHOLESTEROL AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1996-06-11 US disclosed
WO-1996016646-A1 METHOD OF USING TRIARYL-ETHYLENE DERIVATIVES IN THE TREATMENT AND PREVENTION OF OSTEOPOROSIS HOECHST MARION ROUSSEL, INC. (US) 1996-06-06 WO disclosed
WO-1995008528-A1 TRIARYL-ETHYLENE DERIVATIVES FOR USE IN THERAPY MERRELL PHARMACEUTICALS INC. (US) 1995-03-30 WO disclosed